company background image
BRNS logo

Barinthus Biotherapeutics NasdaqGM:BRNS Stock Report

Last Price

US$0.89

Market Cap

US$34.3m

7D

-2.2%

1Y

-58.6%

Updated

20 May, 2025

Data

Company Financials +

Barinthus Biotherapeutics plc

NasdaqGM:BRNS Stock Report

Market Cap: US$34.3m

BRNS Stock Overview

A clinical-stage biopharmaceutical company, focuses on developing immunotherapeutic drug candidates for treating auto-immune and inflammatory diseases. More details

BRNS fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Barinthus Biotherapeutics plc Competitors

Price History & Performance

Summary of share price highs, lows and changes for Barinthus Biotherapeutics
Historical stock prices
Current Share PriceUS$0.89
52 Week HighUS$2.35
52 Week LowUS$0.64
Beta-0.79
1 Month Change21.93%
3 Month Change-16.82%
1 Year Change-58.63%
3 Year Change-77.75%
5 Year Changen/a
Change since IPO-93.69%

Recent News & Updates

Barinthus Biotherapeutics plc (NASDAQ:BRNS) Looks Inexpensive After Falling 29% But Perhaps Not Attractive Enough

Apr 11
Barinthus Biotherapeutics plc (NASDAQ:BRNS) Looks Inexpensive After Falling 29% But Perhaps Not Attractive Enough

Barinthus Biotherapeutics plc (NASDAQ:BRNS) Surges 33% Yet Its Low P/S Is No Reason For Excitement

Jan 10
Barinthus Biotherapeutics plc (NASDAQ:BRNS) Surges 33% Yet Its Low P/S Is No Reason For Excitement

Recent updates

Barinthus Biotherapeutics plc (NASDAQ:BRNS) Looks Inexpensive After Falling 29% But Perhaps Not Attractive Enough

Apr 11
Barinthus Biotherapeutics plc (NASDAQ:BRNS) Looks Inexpensive After Falling 29% But Perhaps Not Attractive Enough

Barinthus Biotherapeutics plc (NASDAQ:BRNS) Surges 33% Yet Its Low P/S Is No Reason For Excitement

Jan 10
Barinthus Biotherapeutics plc (NASDAQ:BRNS) Surges 33% Yet Its Low P/S Is No Reason For Excitement

Barinthus Biotherapeutics plc (NASDAQ:BRNS) Not Doing Enough For Some Investors As Its Shares Slump 32%

Nov 19
Barinthus Biotherapeutics plc (NASDAQ:BRNS) Not Doing Enough For Some Investors As Its Shares Slump 32%

Is Barinthus Biotherapeutics (NASDAQ:BRNS) In A Good Position To Invest In Growth?

Aug 31
Is Barinthus Biotherapeutics (NASDAQ:BRNS) In A Good Position To Invest In Growth?

Here's Why We're Watching Barinthus Biotherapeutics' (NASDAQ:BRNS) Cash Burn Situation

Apr 05
Here's Why We're Watching Barinthus Biotherapeutics' (NASDAQ:BRNS) Cash Burn Situation

We Think Vaccitech (NASDAQ:VACC) Can Afford To Drive Business Growth

Jul 07
We Think Vaccitech (NASDAQ:VACC) Can Afford To Drive Business Growth

Vaccitech's (NASDAQ:VACC) Earnings Are Of Questionable Quality

Nov 17
Vaccitech's (NASDAQ:VACC) Earnings Are Of Questionable Quality

Vaccitech promotes Gemma Brown to CFO

Sep 20

Analysts Just Made An Incredible Upgrade To Their Vaccitech plc (NASDAQ:VACC) Forecasts

Aug 15
Analysts Just Made An Incredible Upgrade To Their Vaccitech plc (NASDAQ:VACC) Forecasts

Vaccitech plc Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Aug 13
Vaccitech plc Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Vaccitech GAAP EPS of $0.41, revenue of $17.06M

Aug 09

Growth Investors: Industry Analysts Just Upgraded Their Vaccitech plc (NASDAQ:VACC) Revenue Forecasts By 51%

May 19
Growth Investors: Industry Analysts Just Upgraded Their Vaccitech plc (NASDAQ:VACC) Revenue Forecasts By 51%

Vaccitech: Aiming For A Cure In Chronic Hepatitis B

Apr 03

Vaccitech: The Next Big Vaccine Trade

Jun 27

Shareholder Returns

BRNSUS BiotechsUS Market
7D-2.2%0.8%1.6%
1Y-58.6%-13.8%11.7%

Return vs Industry: BRNS underperformed the US Biotechs industry which returned -13.8% over the past year.

Return vs Market: BRNS underperformed the US Market which returned 11.7% over the past year.

Price Volatility

Is BRNS's price volatile compared to industry and market?
BRNS volatility
BRNS Average Weekly Movement13.7%
Biotechs Industry Average Movement12.0%
Market Average Movement8.1%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market4.1%

Stable Share Price: BRNS's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: BRNS's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2016105Bill Enrightwww.barinthusbio.com

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapeutic drug candidates for treating auto-immune and inflammatory diseases. Its lead candidate is VTP-1000, which is in Phase 1 clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease. The company is also developing VTP-300, an immunotherapeutic targeting chronic hepatitis B virus infection; VTP-200, a potential non-invasive treatment for persistent high-risk human papillomavirus; VTP-850, an immunotherapeutic candidate for prostate cancer; VTP-600, an immunotherapeutic candidate targeting MAGE-A3 and NY-ESO1 antigens; VTP-500, a prophylactic vaccine candidate to prevent middle east respiratory syndrome; VTP-400, a prophylactic vaccine candidate for shingles; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection.

Barinthus Biotherapeutics plc Fundamentals Summary

How do Barinthus Biotherapeutics's earnings and revenue compare to its market cap?
BRNS fundamental statistics
Market capUS$34.29m
Earnings (TTM)-US$65.23m
Revenue (TTM)US$14.97m
2.4x
P/S Ratio
-0.6x
P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BRNS income statement (TTM)
RevenueUS$14.97m
Cost of Revenue-US$1.10m
Gross ProfitUS$16.07m
Other ExpensesUS$81.30m
Earnings-US$65.23m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-1.62
Gross Margin107.35%
Net Profit Margin-435.79%
Debt/Equity Ratio0%

How did BRNS perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/20 23:15
End of Day Share Price 2025/05/20 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Barinthus Biotherapeutics plc is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James MolloyAlliance Global Partners
Yi ChenH.C. Wainwright & Co.
Matthew HarrisonMorgan Stanley